Intermountain Healthcare Study Finds Vaping Injuries More Difficult to Diagnose During Time of COVID-19 Pandemic

NEXT STORY
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
PREV STORY
Red Cross COVID-19 study shows vulnerable seniors in need of more support
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Loxo Oncology Announces Clinical Proof of Concept Publication for Next-Generation TRK Inhibitor LOXO-195

STAMFORD, Conn., June 03, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company ...

author_avatar
NASDAQ Market News

REACH Air Medical Services Named Program of the Year

SANTA ROSA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- REACH Air Medical Services announced ...

author_avatar
NASDAQ Market News

BluePrint Phase 2 Demonstrates Digital Pathology Review Equivalent to Glass Slides

YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- The BluePrint Phase 2 committee today ...

author_avatar
NASDAQ Market News